Soluble IL-17RCx4 and fusion proteins thereof
US8093355B2 · kind B2 · utility
2Cited by
3References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 15, 2009 |
| Grant date | Jan 10, 2012 |
| Priority date | — |
| Expiry date | Apr 21, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/43
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.